A novel in vitro assay that incorporates hepatic metabolism into hematopoietic toxicity evaluation, addressing a critical gap that standard CFC assays overlook.
By co-culturing pooled hepatocytes and CD34+ cells with novel pharmaceuticals, we can evaluate possible metabolism-dependent toxicity by measuring the clonogenic potential of CD34+ cells in a Colony Forming Cell (CFC) assay. Colony enumeration is executed by experts to ensure accurate and reliable results.
High-quality, assay-ready Gentest® Cryopreserved Pooled Hepatocytes are used in this assay for better consistency, reproducibility, and faster time-to-results.
Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.
Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.
Incorporation of Hepatic Metabolism in the Hematopoietic Stem Cells (HSC) Toxicity Assay via Co-Culturing of HSC with Primary Human HepatocytesAbstracts & Posters
